Literature DB >> 35016592

The impact of caregiver anxiety/depression symptoms and family functioning on child quality of life during pediatric cancer treatment: From diagnosis to 6 months.

Leandra Desjardins1,2, Aden Solomon2, Wendy Shama3, Denise Mills4, Joanna Chung5, Kelly Hancock2, Maru Barrera2.   

Abstract

A pediatric cancer diagnosis can have a significant impact on the quality of life (QOL) of the child. Diagnosis and treatment impact caregiver anxiety/depression symptoms and family functioning, and these in turn may influence child QOL. However, there has been limited longitudinal examination of the impact of both caregiver anxiety/depression symptoms and family functioning on youth QOL at specific points during the early diagnosis and treatment period. Ninety-six caregivers of youth (diagnosed with leukemia/lymphoma or a solid tumor) reported on their own anxiety/depression symptoms, family functioning, demographic and medical factors, and on their child's generic and cancer-specific QOL shortly after diagnosis (T1) and 6 months later (T2). Caregiver anxiety/depression symptoms were associated with poorer cancer-specific and generic child QOL within and across time points. Family conflict was associated with youth cancer-related QOL at T1. Attendance to caregiver anxiety/depression symptoms and family functioning, beginning early in the cancer trajectory, is an important aspect of family-centered care. Routine psychosocial screening and triage may help identify and intervene to support both caregiver and child psychosocial well-being.

Entities:  

Keywords:  Pediatric; anxiety/depression; cancer; family; quality of life; quantitative

Year:  2022        PMID: 35016592     DOI: 10.1080/07347332.2021.2015646

Source DB:  PubMed          Journal:  J Psychosoc Oncol        ISSN: 0734-7332


  1 in total

1.  Quality of life in mothers and fathers of children treated for acute lymphoblastic leukaemia in Sweden, Finland and Denmark.

Authors:  Nina Mogensen; Ella Saaranen; Erik Olsson; Birgitte Klug Albertsen; Päivi M Lähteenmäki; Ulrika Kreicbergs; Mats Heyman; Arja Harila-Saari
Journal:  Br J Haematol       Date:  2022-07-19       Impact factor: 8.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.